News

The trial is evaluating 4D-150 in patients with wet age-related macular degeneration (wet AMD).

Host Deborah Ristvedt, DO, is joined by Marguerite B. McDonald, MD, FACS, to discuss her journey with pioneering contributions to ophthalmology, patient-centered care, leadership, and guidance for the next generation.

Johnson & Johnson reaches 100,000 TECNIS ODYSSEY IOLs implanted, and presented data on in vision correction and patient satisfaction at the AAO 2025 meeting.

Data suggests that EYP-1901 can reduce the number of injections and treatment burden for patients

A mutation-agnostic gene therapy approach offers new possibilities for patients, especially those with inherited retinal diseases.

The VITA Trial is a prospective pilot study on the VisiPlate Aqueous Shunt in patients with with open-angle glaucoma.

The addition comes as the company accelerates development of its long-acting anti-VEGF program and advances its HA-binding platform.

The trial met both its primary efficacy and key secondary endpoints.

Adverum Biotechnologies is known for its therapeutic candidate Ixo-vec, in development for the treatment of wet age-related macular degeneration (AMD)

The trial will be evaluating AXPAXLI dosed every 6 months versus aflibercept (2 mg) dosed every 8 weeks in treatment-naïve wet AMD patients.

Under the terms of the agreement, 4DMT will grant Otsuka exclusive rights to develop and commercialize 4D-150 for retinal vascular diseases in Japan, China, Australia, and other Asia-Pacific markets.

Both business moves further align Topcon with a long-term strategy for promoting data-driven predictive healthcare

The funding will support the completion of the clinical PoC of its AAVB-039 CELESTE study and the completion of the STELLA natural history study

Veligrotug is an intravenously delivered, anti-insulin-like growth factor-1 receptor (IGF-1R) antibody for the treatment of thyroid eye disease (TED).

In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr Feistmann in an overview of office-based surgery, with actionable advice for retina specialists considering this approach.

Tsu Shan Chambers, optometrist and filmmaker, blends clinical insight and storytelling to highlight preventable vision loss, retinitis pigmentosa, and the power of ability over disability in her socially conscious film.

Catch up on this week's highlights in retina.

To celebrate Ophthalmology Times' 50th anniversary, we asked leading experts what the practice would look like today had optical coherence tomography (OCT), one of the biggest innovations in the field, never been invented.

Clinicians discuss how the treatment compares with epi-off cross-linking, what may shape adoption, and how patient outcomes could improve.

Marguerite B. McDonald, MD, FACS, reflects on a first-year residency case that taught her the importance of trusting her instincts and advocating for patient safety.

Dr. James Chelnis explores innovative energy-based technologies in aesthetic facial surgery, emphasizing safety, personalized treatments, and future advancements in patient care.

Ophthalmologists discuss topography-guided techniques, long-term corneal health, and emerging technologies set to transform refractive surgery.

Specialists discuss diagnostic technologies, treatment strategies, and research that are improving outcomes for young patients

Deborah A. Ferrington, PhD, highlights how breakthroughs in imaging, AI, and stem cell research are reshaping ophthalmology.

The professor from Wills Eye Hospital in Philadelphia, Pennsylvania, explained why it's time to retire the term "sterile" when addressing culture-negative endophthalmitis

To celebrate Ophthalmology Times' 50th anniversary, we asked leading experts what the practice would look like today had optical coherence tomography (OCT), one of the biggest innovations in the field, never been invented.

Deborah Ristvedt, DO, recalls a retinal detachment repair that took an unexpected turn, teaching lasting lessons in patient awareness and surgical presence.